Pyridinoline cross-linked carboxyterminal telopeptide of type I collagen as a useful marker for monitoring metastatic bone activity in men with prostate cancer

Journal of Urology

Volumn 166, Issue 3, 2001, Pages 1106-1110

  Noguchi, Masanori ^a   Noda, Shinshi ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Bone and bones; Neoplasm metastasis; Prostate; Prostatic neoplasms; Tumor markers, biological

Indexed keywords

BIOLOGICAL MARKER; COLLAGEN TYPE 1; PROSTATE SPECIFIC ANTIGEN; PYRIDINOLINE; TUMOR MARKER;

ADULT; AGED; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; CANCER HORMONE THERAPY; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; CROSS LINKING; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER;

EID: 0034889634     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)65930-7     Document Type: Article

References (29)

1. Comparison of enzyme, clinical, radiographic, and radionuclide methods of detecting bone metastases from carcinoma of the prostate
2. Some limitations of the radioisotope bone scan in patients with metastatic prostatic cancer: A subanalysis of EORTC trial 30853
3. The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer
4. Correlation between bone metabolic markers and bone scan in prostatic cancer
5. Prostate specific antigen and bone scan correlation in the staging and monitoring of patients with prostate cancer
6. Prostate specific antigen in the staging of localized prostate cancer: Influence of tumor differentiation, tumor volume and benign hyperplasia
7. Biochemical markers and skeletal metastases
8. Radioimmunoassay of the carboxyterminal propeptide of human type I procollagen
9. Procollagen type I carboxy-terminal propeptide as a marker of osteoblastic bone metastases
10. Radioimmunoassay for the pyridinoline cross-linked carboxyterminal telopeptide of type I collagen: A new serum marker of bone collagen degradation
11. Carcinoma of the prostate
12. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan
13. Recent advances in biochemical markers of bone turnover
14. Differential patterns of bone turnover in relation to bone pain and disease extent in bone in cancer patients with skeletal metastases
15. Markers of type I collagen degradation and synthesis in the monitoring of treatment response in bone metastases from breast carcinoma
16. Osteocalcin: Is it a useful marker of bone metastasis and response to treatment in advanced prostate cancer?
17. Type I collagen degradation product (ICTP) gives information about the nature of bone metastases and has prognostic value in prostate cancer
18. The value of serum carboxyterminal propeptide of type 1 procollagen in predicting bone metastases in prostate cancer
19. Comparison of markers of bone formation and resorption in prostate cancer patients to predict bone metastasis
20. Inability of bone turnover marker as a strong prognostic indicator in prostate cancer patients with bone metastasis: Comparison with the extent of disease (EOD) grade
21. Use of bone turnover marker, pyridinoline cross-linked carboxyterminal telopeptide of type I collagen (ICTP), in the assessment and monitoring of bone metastasis in prostate cancer
22. Generalized increase in bone resorption in carcinoma of the prostate
23. Histomorphometric analysis of sclerotic bone metastases from prostate carcinoma with special reference to osteoalacia
24. Disodium pamidronate identifies differential osteoclastic bone resorption in metastatic prostate cancer
25. Clinical efficacy of bone alkaline phosphatase and prostate specific antigen in the diagnosis of bone metastasis in prostate cancer
26. Prostate specific antigen and bone scan correlation in the staging and monitoring of patients with prostatic cancer
27. A reappraisal of serial isotope bone scans in prostate cancer
28. Evaluation of the effect of oral clodronate on skeletal metastases with type I collagen metabolites. A controlled trial of the Finnish Prostate Cancer Group
29. Prostate specific antigen in hormonally treated stage D2 prostate cancer: Is it always an accurate indicator of disease status?